Skip to main content

Table 1 Patient characteristics at baseline

From: A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

 

Mean ± SD or n/N (%)

Age (years)

60.3 ± 7.6

Female

23/59 (39.0)

Weight (kg)

87.4 ± 13

Height (cm)

171 ± 11

BMI (kg/m2)

29.9 ± 4.3

Mean duration of diabetes (years)

5.54 ± 4.9

HbA1c

6.67 ± 0.7% (49 mmol/mol)

Glucose

Fasting (mg/dl)

132 ± 28

Postprandiala (mg/dl)

178 ± 66

Fasting Insulin (mU/l)

12.1 ± 7.4

HOMA index

4.02 ± 2.8

Office blood pressure (mmHg)

Systolic

130 ± 14

Diastolic

79 ± 9

Lipids (mg/dl)

LDL-C

143 ± 32

HDL-C

48.2 ± 11

Total cholesterol

207 ± 39

Triglycerides

149 ± 66

  1. N = 59
  2. BMI body mass index, HbA1c glycosylated haemoglobin, HOMA homeostatic model assessment, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
  3. a A standardised breakfast was given